These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 34988780)

  • 1. Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology.
    Tompson D; Whitaker M; Pan R; Johnson G; Fuller T; Zann V; McKenzie L; Abbott-Banner K; Hawkins S; Powell M
    Pharm Res; 2022 Jan; 39(1):153-165. PubMed ID: 34988780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772.
    Tompson DJ; Whitaker M; Pan R; Johnson G; Fuller T; McKenzie L; Zann V; Powell M; Abbott-Banner K; Hawkins S
    Pharm Res; 2021 Jul; 38(7):1235-1245. PubMed ID: 34136987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.
    Weisel K; Scott NE; Tompson DJ; Votta BJ; Madhavan S; Povey K; Wolstenholme A; Simeoni M; Rudo T; Richards-Peterson L; Sahota T; Wang JG; Lich J; Finger J; Verticelli A; Reilly M; Gough PJ; Harris PA; Bertin J; Wang ML
    Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects.
    Tompson DJ; Davies C; Scott NE; Cannons EP; Kostapanos M; Gross AS; Powell M; Ino H; Shimamura R; Ogura H; Nagakubo T; Igarashi H; Nakano A
    Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):71-83. PubMed ID: 33165774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis.
    Weisel K; Scott N; Berger S; Wang S; Brown K; Powell M; Broer M; Watts C; Tompson DJ; Burriss SW; Hawkins S; Abbott-Banner K; Tak PP
    BMJ Open Gastroenterol; 2021 Aug; 8(1):. PubMed ID: 34389633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis.
    Weisel K; Berger S; Thorn K; Taylor PC; Peterfy C; Siddall H; Tompson D; Wang S; Quattrocchi E; Burriss SW; Walter J; Tak PP
    Arthritis Res Ther; 2021 Mar; 23(1):85. PubMed ID: 33726834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
    Dulac O; Alvarez JC
    Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food.
    Lamba M; Wang R; Fletcher T; Alvey C; Kushner J; Stock TC
    J Clin Pharmacol; 2016 Nov; 56(11):1362-1371. PubMed ID: 26970526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers.
    Delrat P; Paraire M; Jochemsen R
    Biopharm Drug Dispos; 2002 May; 23(4):151-7. PubMed ID: 12015789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs. immediate-release formulations.
    Brittain ST; Wheless JW
    Epilepsy Behav; 2015 Nov; 52(Pt A):31-6. PubMed ID: 26409125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen.
    Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
    Transplant Proc; 2005 Mar; 37(2):867-70. PubMed ID: 15848559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of loratadine and pseudoephedrine following single and multiple doses of once- versus twice-daily combination tablet formulations in healthy adult males.
    Kosoglou T; Radwanski E; Batra VK; Lim JM; Christopher D; Affrime MB
    Clin Ther; 1997; 19(5):1002-12. PubMed ID: 9385487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of a new once-daily controlled-release sarpogrelate hydrochloride compared with immediate-release formulation and the effect of food.
    Kim TE; Kim JR; Jung JA; Kim MJ; Lee SY; Ko JW; Jung WT; Choi YW; Lee HJ; Kim SH; Huh W
    J Clin Pharm Ther; 2014 Apr; 39(2):192-5. PubMed ID: 24325365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects.
    Danto SI; Shojaee N; Singh RSP; Li C; Gilbert SA; Manukyan Z; Kilty I
    Arthritis Res Ther; 2019 Dec; 21(1):269. PubMed ID: 31805989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
    Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
    Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo performance of an oral MR matrix tablet formulation in the beagle dog in the fed and fasted state: assessment of mechanical weakness.
    McInnes F; Clear N; Humphrey M; Stevens HN
    Pharm Res; 2008 May; 25(5):1075-84. PubMed ID: 17917709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen.
    Florman S; Alloway R; Kalayoglu M; Lake K; Bak T; Klein A; Klintmalm G; Busque S; Brandenhagen D; Lake J; Wisemandle K; Fitzsimmons W; First MR
    Transplant Proc; 2005 Mar; 37(2):1211-3. PubMed ID: 15848672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.